Ascidian and Lilly signed a collaboration today to use Ascidian's RNA exon editing platform for monogenic kidney diseases, potentially worth up to $1.9 billion in milestones
- 2 days ago
- 1 min read
Ascidian CEO Mike Ehlers tells us about the deal and discusses the technology and the potential benefits of it over DNA editing and other genetic medicine approaches.









.png)
